BioWorld

July 14, 2009

Tarceva Survival Data Intensify Lung Cancer Maintenance Battle

It's been barely a week since Eli Lilly and Co.'s chemotherapy drug Alimta (pemetrexed) received the first-ever FDA approval in the maintenance treatment of lung cancer, and already the competition is closing in. (BioWorld Today) Read More

Antiplatelet Space Growing, Plavix Still Strong - for Now

Mixed News on H1N1 Emerges from WHO and Nature Study

NewCo News: Cardioxyl's Nitroxyl Donor Drug Starts Testing in Heart Failure

HHS Piles on Swine Flu Money: $884M More for H1N1 Vaccine

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 12, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld Science

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...